{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:58:13Z","timestamp":1792112293215,"version":"4.4.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"None"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s40263-023-01023-6","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T17:01:43Z","timestamp":1689008503000},"page":"655-660","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit Hyperactivity Disorder"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7480-7008","authenticated-orcid":false,"given":"Maxwell Z.","family":"Price","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,10]]},"reference":[{"issue":"6","key":"1023_CR1","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s40263-021-00825-w","volume":"35","author":"RL Findling","year":"2021","unstructured":"Findling RL, Candler SA, Nasser AF, et al. Viloxazine in the management of CNS disorders: a historical overview and current status. CNS Drugs. 2021;35(6):643\u201353. https:\/\/doi.org\/10.1007\/s40263-021-00825-w.","journal-title":"CNS Drugs"},{"issue":"8","key":"1023_CR2","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.clinthera.2020.05.021","volume":"42","author":"A Nasser","year":"2020","unstructured":"Nasser A, Liranso T, Adewole T, et al. A phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended-release) in the treatment of attention-deficit\/hyperactivity disorder in school-age children. Clin Ther. 2020;42(8):1452\u201366. https:\/\/doi.org\/10.1016\/j.clinthera.2020.05.021.","journal-title":"Clin Ther"},{"issue":"8","key":"1023_CR3","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s40263-022-00938-w","volume":"36","author":"A Nasser","year":"2022","unstructured":"Nasser A, Hull JT, Chaturvedi SA, et al. A phase III, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of viloxazine extended-release capsules in adults with attention-deficit\/hyperactivity disorder. CNS Drugs. 2022;36(8):897\u2013915. https:\/\/doi.org\/10.1007\/s40263-022-00938-w.","journal-title":"CNS Drugs"},{"key":"1023_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2147\/jep.s256586","volume":"12","author":"C Yu","year":"2020","unstructured":"Yu C, Garcia-Olivares J, Candler S, et al. New insights into the mechanism of action of viloxazine: serotonin and norepinephrine modulating properties. J Exp Pharmacol. 2020;12:285\u2013300. https:\/\/doi.org\/10.2147\/jep.s256586.","journal-title":"J Exp Pharmacol"},{"key":"1023_CR5","doi-asserted-by":"publisher","unstructured":"ACNP 61st Annual meeting: Poster abstracts P271-P540. Neuropsychopharmacol. 2022;47(S1):220-370. https:\/\/doi.org\/10.1038\/s41386-022-01485-0.","DOI":"10.1038\/s41386-022-01485-0"},{"key":"1023_CR6","unstructured":"Strattera\u2014Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/021411s004s012s013s015s021lbl.pdf. Accessed 24 Oct 2022."},{"key":"1023_CR7","unstructured":"Qelbree\u2014Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/211964s003lbl.pdf. Accessed 24 Oct 2022."},{"key":"1023_CR8","first-page":"1","volume-title":"ADHD Rating Scale\u20145 for children and adolescents: checklists, norms, and clinical interpretation","author":"GJ DuPaul","year":"2016","unstructured":"DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD Rating Scale\u20145 for children and adolescents: checklists, norms, and clinical interpretation. New York: The Guilford Press; 2016. p. 1\u20136."},{"issue":"1","key":"1023_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/1087054709347435","volume":"14","author":"TJ Spencer","year":"2009","unstructured":"Spencer TJ, Adler LA, Qiao M, et al. Validation of the adult ADHD Investigator Symptom Rating Scale (AISRS). J Atten Disord. 2009;14(1):57\u201368. https:\/\/doi.org\/10.1177\/1087054709347435.","journal-title":"J Atten Disord"},{"key":"1023_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.14344","author":"W Chung","year":"2019","unstructured":"Chung W, Jiang S-F, Paksarian D, et al. Trends in the prevalence and incidence of attention-deficit\/hyperactivity disorder among adults and children of different racial and ethnic groups. JAMA Netw Open. 2019. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.14344.","journal-title":"JAMA Netw Open"},{"key":"1023_CR11","doi-asserted-by":"publisher","first-page":"108297","DOI":"10.1016\/j.drugalcdep.2020.108297","volume":"217","author":"AR Board","year":"2020","unstructured":"Board AR, Guy G, Jones CM, et al. Trends in stimulant dispensing by age, sex, state of residence, and prescriber specialty\u2014United States, 2014\u20132019. Drug Alcohol Depend. 2020;217:108297. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108297.","journal-title":"Drug Alcohol Depend"},{"issue":"06","key":"1023_CR12","doi-asserted-by":"publisher","first-page":"754","DOI":"10.4088\/jcp.08m04902pur","volume":"71","author":"SV Faraone","year":"2009","unstructured":"Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit\/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiat. 2009;71(06):754\u201363. https:\/\/doi.org\/10.4088\/jcp.08m04902pur.","journal-title":"J Clin Psychiat"},{"issue":"5","key":"1023_CR13","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/00004583-200405000-00009","volume":"43","author":"A Charach","year":"2004","unstructured":"Charach A, Ickowicz A, Schachar R. Stimulant treatment over five years: adherence, effectiveness, and adverse effects. J Am Acad Child Psy. 2004;43(5):559\u201367. https:\/\/doi.org\/10.1097\/00004583-200405000-00009.","journal-title":"J Am Acad Child Psy."},{"key":"1023_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-9-95","author":"GM Pohl","year":"2009","unstructured":"Pohl GM, Van Brunt DL, Ye W, et al. A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit\/hyperactivity disorder (ADHD). BMC Health Serv Res. 2009. https:\/\/doi.org\/10.1186\/1472-6963-9-95.","journal-title":"BMC Health Serv Res"},{"issue":"20","key":"1023_CR15","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1001\/jama.2021.6118","volume":"325","author":"E Harstad","year":"2021","unstructured":"Harstad E, Shults J, Barbaresi W, et al. \u03912-adrenergic agonists or stimulants for preschool-age children with attention-deficit\/hyperactivity disorder. JAMA. 2021;325(20):2067. https:\/\/doi.org\/10.1001\/jama.2021.6118.","journal-title":"JAMA"},{"key":"1023_CR16","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.s59270","author":"A Childress","year":"2015","unstructured":"Childress A. A critical appraisal of atomoxetine in the management of ADHD. Ther Clin Risk Manag. 2015. https:\/\/doi.org\/10.2147\/tcrm.s59270.","journal-title":"Ther Clin Risk Manag"},{"issue":"11","key":"1023_CR17","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s40263-013-0102-x","volume":"27","author":"V Sikirica","year":"2013","unstructured":"Sikirica V, Findling RL, Signorovitch J, et al. Comparative efficacy of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit\/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology. CNS Drugs. 2013;27(11):943\u201353. https:\/\/doi.org\/10.1007\/s40263-013-0102-x.","journal-title":"CNS Drugs"},{"key":"1023_CR18","unstructured":"Thomas Jordan MD. Viloxazine for ADHD. CARLAT PUBLISHING RSS. https:\/\/www.thecarlatreport.com\/articles\/3575-viloxazine-for-adhd. Published October 6, 2022. Accessed 5 Feb 2023."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01023-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-023-01023-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-023-01023-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T11:16:57Z","timestamp":1693567017000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-023-01023-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1023"],"URL":"https:\/\/doi.org\/10.1007\/s40263-023-01023-6","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"27 June 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The open access fee was funded by the investigators: Maxwell Z. Price and Richard L. Price.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Maxwell Z. Price certifies that there is no conflict of interest with any financial organization regarding the material discussed in the manuscript. Richard L. Price has received honoraria from AbbVie, Alkermes, Idorsia, Intra-Cellular Therapies, Janssen, Jazz, Lundbeck, Neuronetics, Otsuka, and Supernus, and discloses no other conflicts of interest in this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"This research study was conducted retrospectively from data obtained for clinical purposes and performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. We consulted extensively with WCG IRB, who determined that our study did not need ethical approval. An IRB official waiver of ethical approval (#1-1597751-1) was granted from WCG IRB.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study (or their parent or legal guardian in the case of children under 16 years).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Both authors substantially contributed to the conception and design of the work, drafting the work, and approving the final version to be published, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy of any part of the work are appropriately investigated and resolved. Both authors read and approved the final version of the manuscript and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}